Syntropy to Unlock the Value of Scientific Data in Fight to End Cancer

MerckMerck, a leading science and technology company, and software company Palantir Technologies, today announced their intent to form a joint venture under the brand name Syntropy. Syntropy is expected to empower scientists and research centers with a collaborative technology platform to advance cancer research, help drive scientific discovery, and improve human lives.

Research institutions around the world are generating a rapidly growing amount of biomedical data, but much of it is trapped in silos within and between institutions. Today, this critical data is often inaccessible to the scientists and clinicians who need it to advance their work. Syntropy aims to unlock the value of this untapped data, enabling the world's leading experts to collaborate in the fight against cancer and many other diseases.

"The success of science hinges on the ability to act on insights," said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck. "We expect Syntropy to facilitate collaboration within the global scientific community, in order to drive breakthrough innovation in cancer research."

"Unlocking the power of scientific data is critical to advancing the fight against cancer," said Alexander Karp, Palantir co-founder and CEO. "Syntropy aims to help researchers collaborate securely to realize the value of this data, driving discoveries that will deliver better treatments to patients faster."

Syntropy's user-centric data integration platform is powered by Palantir Foundry, which allows users to structure and analyze data from disparate sources, enabling experts to more quickly act on novel research insights and advance patient care, while safeguarding data ownership. Syntropy is expected to also facilitate the secure, transparent sharing of data between participating researchers and institutions, creating an ecosystem that incentivizes collaboration and ultimately accelerates scientific discovery.

About Syntropy

Syntropy shall be a joint venture between a new subsidiary of Merck, which is independent from its existing healthcare, life science and performance materials business sectors, and Palantir Technologies, aimed at unlocking the value of scientific biomedical data. Syntropy is expected to serve as a catalyst for change in scientific research by equipping scientists with more intuitive and effective tools for unlocking the value of their data, while creating an ecosystem that brings together leading scientific experts to win the fight against cancer and countless other diseases. Syntropy is expected to be headquartered in Boston, MA. Merck and Palantir Technologies have signed a non-binding term sheet to initiate the creation of Syntropy.

About Merck

Merck, the vibrant science and technology company, operates across healthcare, life science and performance materials. Around 53,000 employees work to make a positive difference to millions of peoples’ lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enable the intelligence of devices - the company is everywhere. In 2017, Merck generated sales of € 15.3 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1666, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

About Palantir

Palantir Technologies is a software company that builds enterprise data platforms for organizations with highly complex and sensitive data environments. From building safer cars and planes, to discovering new drugs and combatting terrorism, Palantir helps customers across the public, private, and nonprofit sectors transform the way they use their data. Palantir is headquartered in Palo Alto, with major offices in New York, Washington, D.C., London, Paris, and Munich.

Most Popular Now

A New Machine Learning Model can Classif…

Machine learning has improved dramatically in recent years and shown great promise in the field of medical image analysis. A team of research specialists at Dartmouth's Norris Cotton Cancer Center...

Could Blockchain Ensure Integrity of Cli…

UC San Francisco researchers have created a proof-of-concept method for ensuring the integrity of clinical trials data with blockchain. The system creates an immutable audit trail that makes it easy...

3D Child Welfare: How Data, Design and D…

Opinion Article by Rainer Binder, Managing Director, Global Employment and Social Services, Accenture Child welfare remains a pressing challenge for governments around the world, and the statistics are heart-breaking. In the...

Bringing more Human Intelligence to AI, …

The advent of data science, wireless connectivity and sensors, artificial intelligence (AI), and the Internet of Things (IoT) has raised the prospects for digital automation, smart hospital design and the...

Scotland's Digital Health Leaders Recogn…

Scotland's digital health champions have been recognised for their achievements at the Holyrood Connect Digital Health and Care Awards 2019. William Edwards, director of eHealth at NHS Greater Glasgow and...

DMEA 2019: International Exchange on Dig…

9 - 11 April 2019, Berlin, Germany. DMEA (formerly conhIT) is the industry's main event for digital healthcare. In that context, an international exchange of experiences and networking beyond national borders...

Philips to Expand its Radiology Informat…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has signed an agreement to acquire the Healthcare Information Systems business of Carestream Health...

Three Winners of 2019 Sandoz Healthcare …

Sandoz, a Novartis division, announced the winners of the 2019 Sandoz Healthcare Access Challenge (HACk). Sandoz HACk invites entrepreneurs and innovators in the field of digital technology to submit ideas...

UK Sales of Xanax and other Prescription…

Sales of prescription psychiatric drugs such as Xanax and diazepam via darknet online drug markets have increased in the UK at an alarming rate, according to new research by the...

Accenture Wins GLOMO Award for Virtual R…

The Accenture (NYSE: ACN) Virtual Experience Solutions (AVEnueS) has won "Best Mobile VR or AR" at the GSMA GLOMO Awards 2019. The award was presented at MWC19 Barcelona.

Study Finds Robots can Detect Breast Can…

Breast cancer is the most common cancer in women, and despite important improvements in therapy, it is still a major cause for cancer-related mortality, accounting for approximately 500,000 annual deaths...